Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Risk group stratification to predict prognosis in Japanese patients with urothelial carcinoma

Funder: Japan Society for the Promotion of Science

Funding period
JPY 5.1 M
USD 53 K
Funding amount
Abstract
Combined ERCC1 and XRCC1 expression may serve as an independent prognostic marker for survival in bladder cancer patients receiving combined trimodality therapy. Prospective studies with a larger sample size are required to confirm these results.Risk group stratification based on preoperative clinical T stage, voided urine cytology, and WBC counts may be useful for selection of UUT-UC patients for neoadjuvant chemotherapy. Prospective studies with larger numbers of patients and a longer follow-up period are needed to confirm our results.UTUC with variant histology might be a phenotype of high-grade, locally aggressive advanced tumors rather than of systemic disease. Variant histology may be useful for selection of patients with pT3 and more invasive UTUC for adjuvant therapy. Prospective studies in a larger number of patients with a centralized pathological review are needed to confirm our results.
Similar projects All >
Sorted by: Start Date
Project list item
Clonal evolution and molecular stratification of urothelial carcinoma in situ of the urinary bladder

German Research Foundation to Stefan Garczyk, Nadine Gaisa

 
2019 -
Project list item
Upper tract urothelial carcinoma is non-basal and T-cell depleted

Bladder Cancer Advocacy Network to Panagiotis Vlachostergios

USD 1,700
2018 - 2018
Project list item
Next generation sequencing to enhance initial staging and dynamically monitor disease response in upper tract urothelial carcinoma

Bladder Cancer Advocacy Network to Philip Hilmi Abbosh, Wafik El-Deiry, Elizabeth Plimack

USD 50,000
2018 - 2020
Project list item
Ascertaining the role of mutations in COMPASS-like complex members in the development of upper tract urothelial carcinoma

Bladder Cancer Advocacy Network to Byron H Lee, Nima Sharifi, Ming Hu, Daniel Kim

USD 50,000
2017 - 2018

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Patient Safety

  • RCDC

    Rare Diseases

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • Health Research Areas

    Clinical

  • Broad Research Areas

    Clinical Medicine and Science